Cargando…
The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy
PURPOSE: To examine the validity of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for the assessment of function in a community-based sample of patients with chronic pain conditions undergoing evaluation for chronic opioid therapy. PATIENTS AND METHODS: One hundred ni...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6573777/ https://www.ncbi.nlm.nih.gov/pubmed/31354334 http://dx.doi.org/10.2147/JPR.S207870 |
_version_ | 1783427782415482880 |
---|---|
author | Wawrzyniak, Kelly M Finkelman, Matthew Schatman, Michael E Kulich, Ronald J Weed, Valerie F Myrta, Eura DiBenedetto, David J |
author_facet | Wawrzyniak, Kelly M Finkelman, Matthew Schatman, Michael E Kulich, Ronald J Weed, Valerie F Myrta, Eura DiBenedetto, David J |
author_sort | Wawrzyniak, Kelly M |
collection | PubMed |
description | PURPOSE: To examine the validity of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for the assessment of function in a community-based sample of patients with chronic pain conditions undergoing evaluation for chronic opioid therapy. PATIENTS AND METHODS: One hundred nine of 124 patients were evaluated for a chronic opioid therapy program between December 1, 2014 and April 10, 2015, inclusive, at one community-based interdisciplinary pain management practice. Measures included: demographic data; the WHODAS 2.0; a modified version of the Roland Morris Disability Questionnaire (RMDQ-m); the Patient Health Questionnaire-9 item (PHQ-9); the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R); the Current Opioid Misuse Measure (COMM), the Opioid Risk Tool (ORT); opioid dose. These data were collected as part of routine care, and this retrospective chart review study examined the data from this convenience sample, comparing the results of each assessment tool to the results of the WHODAS 2.0. RESULTS: Median score on the WHODAS 2.0 was 25.69 (IQR=16.01 to 35.28). WHODAS 2.0 score was significantly correlated with the RMDQ-m (r(s)=0.69, p<0.001), the PHQ-9 (r(s)=0.68, p<0.001), the COMM (r(s)=0.52, p<0.001) and the SOAPP-R (r(s)=0.51, p<0.001). There was no significant correlation between the WHODAS 2.0 and the ORT (r(s)=0.14, p=0.12) or opioid dose (r(s)=0.07, p=0.47). CONCLUSIONS: The WHODAS 2.0 was significantly positively correlated with other measures, including measures of disability, risk of opioid misuse, and depression among patients being evaluated for chronic opioid therapy. The WHODAS 2.0 may be a useful measure of disability across a number of important domains when discussing expectations of both patients and providers at initiation of opioid therapy for chronic pain management. This assessment and discussion is crucial, particularly given the focus on function, rather than analgesia alone, when evaluating the effectiveness of opioid treatment. |
format | Online Article Text |
id | pubmed-6573777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65737772019-07-26 The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy Wawrzyniak, Kelly M Finkelman, Matthew Schatman, Michael E Kulich, Ronald J Weed, Valerie F Myrta, Eura DiBenedetto, David J J Pain Res Original Research PURPOSE: To examine the validity of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) for the assessment of function in a community-based sample of patients with chronic pain conditions undergoing evaluation for chronic opioid therapy. PATIENTS AND METHODS: One hundred nine of 124 patients were evaluated for a chronic opioid therapy program between December 1, 2014 and April 10, 2015, inclusive, at one community-based interdisciplinary pain management practice. Measures included: demographic data; the WHODAS 2.0; a modified version of the Roland Morris Disability Questionnaire (RMDQ-m); the Patient Health Questionnaire-9 item (PHQ-9); the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R); the Current Opioid Misuse Measure (COMM), the Opioid Risk Tool (ORT); opioid dose. These data were collected as part of routine care, and this retrospective chart review study examined the data from this convenience sample, comparing the results of each assessment tool to the results of the WHODAS 2.0. RESULTS: Median score on the WHODAS 2.0 was 25.69 (IQR=16.01 to 35.28). WHODAS 2.0 score was significantly correlated with the RMDQ-m (r(s)=0.69, p<0.001), the PHQ-9 (r(s)=0.68, p<0.001), the COMM (r(s)=0.52, p<0.001) and the SOAPP-R (r(s)=0.51, p<0.001). There was no significant correlation between the WHODAS 2.0 and the ORT (r(s)=0.14, p=0.12) or opioid dose (r(s)=0.07, p=0.47). CONCLUSIONS: The WHODAS 2.0 was significantly positively correlated with other measures, including measures of disability, risk of opioid misuse, and depression among patients being evaluated for chronic opioid therapy. The WHODAS 2.0 may be a useful measure of disability across a number of important domains when discussing expectations of both patients and providers at initiation of opioid therapy for chronic pain management. This assessment and discussion is crucial, particularly given the focus on function, rather than analgesia alone, when evaluating the effectiveness of opioid treatment. Dove 2019-06-10 /pmc/articles/PMC6573777/ /pubmed/31354334 http://dx.doi.org/10.2147/JPR.S207870 Text en © 2019 Wawrzyniak et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wawrzyniak, Kelly M Finkelman, Matthew Schatman, Michael E Kulich, Ronald J Weed, Valerie F Myrta, Eura DiBenedetto, David J The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
title | The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
title_full | The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
title_fullStr | The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
title_full_unstemmed | The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
title_short | The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
title_sort | world health organization disability assessment schedule-2.0 (whodas 2.0) in a chronic pain population being considered for chronic opioid therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6573777/ https://www.ncbi.nlm.nih.gov/pubmed/31354334 http://dx.doi.org/10.2147/JPR.S207870 |
work_keys_str_mv | AT wawrzyniakkellym theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT finkelmanmatthew theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT schatmanmichaele theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT kulichronaldj theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT weedvalerief theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT myrtaeura theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT dibenedettodavidj theworldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT wawrzyniakkellym worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT finkelmanmatthew worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT schatmanmichaele worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT kulichronaldj worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT weedvalerief worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT myrtaeura worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy AT dibenedettodavidj worldhealthorganizationdisabilityassessmentschedule20whodas20inachronicpainpopulationbeingconsideredforchronicopioidtherapy |